Loading...
OTC Markets
Totals
Securities
12,214
Dollar Vol
$2.7B
Share Vol
3.1B
Trades
358,241

OTC Markets Group uses cookies and similar technologies to help us understand how you use our websites, as further disclosed in our Privacy Policy. Our Terms of Service contain important information including restrictions on your use of our websites. By clicking “Accept”, or by continuing to use our websites, you consent to the use of cookies and agree to the terms of the OTC Markets Group Privacy Policy and Terms of Service.

GTBP
GT Biopharma Inc.

Common Stock

2.06

0.03

1.48%

Delayed (15 Min) Trade Data: 12:00am 07/18/2025
GT Biopharma Inc. Company Logo

8000 Marina Blvd.

Suite 100

Brisbane, CA 94005

Business Description
At GT Biopharma, Inc., we are developing innovative drugs for the treatment of cancers.
Financial Reporting
Reporting Status
U.S. Reporting: SEC Reporting
Audited Financials
Audited
Latest Report
CIK
0000109657
Fiscal Year End
12/31
Company Officers & Contacts
Anthony Cataldo
CEO, CFO, Chairman of the Supervisory Board

Mr. Cataldo founded GT Biopharma Inc. upon joining the Board of Directors and subsequently Chairman and CEO in in July of 2014, where he changed the Company's profile with the inclusion of oncology assets. From February 2011 to June 2013 Mr. Cataldo served as Founder and Chairman/CEO of Genesis Biopharma, Inc., now known as Iovance Biotherapeutics, Inc., (IOVA). Mr. Cataldo created the highly successful IOVA/Genesis with the inclusion of assets acquired from the National Cancer Institute for the treatment of stage four melanoma. Mr. Cataldo has extensive experience in the biotechnology sector having served as Chairman/CEO of several biotech companies including: Calypte Biomedical Corporation, and Senetek, PLC.

Steven W. Weldon
CFO

Mr. Weldon joined the GT Biopharma, lnc, Inc. team as a member of the Board of Directors in September 2014. He was appointed Chief Financial Officer in November 2014. Mr. Weldon was elected President of GT Biopharma, Inc. November 19, 2014. Mr. Weldon is a certified public accountant licensed to practice in the state of Florida. Mr. Weldon has over 15 years of financial and accounting experience with public and private companies. He most recently was the CFO of Grow BLOX (GBLX). Steven received his Bachelor of Science degree and his Masters in Business Administration from Florida Southern College, where he was an adjunct professor. Mr. Weldon has years of experience as board member, Chief Financial Officer and Chief Executive Officer of publicly traded companies.

Board of Directors

Not available

Other Company Insiders

Not available

Other Company Insiders are all persons or entities beneficially owning 10% or more of any class of the issuer's securities. Together, officers, directors and other company insiders comprise Company Insiders.
Service Providers
Accounting/Auditing Firm
Seligson & Giannattasio, LLP

726 N Broadway

White Plains, NY 10603

Investment Bank
Dawson James Securities, Inc.

101 N. Federal Highway

Suite 600

Boca Raton, FL 33432

Securities Counsel
Baker McKenzie

1901 Avenue of the Stars

Suite 950

Los Angeles, CA 90067

Profile Data
SIC - Industry Classification
2834 - Pharmaceutical preparations
Incorporation Information
DE, US, 1974
Employees
2 as of 05/11/2020
Shell
No
Products and Services

Not available

Company Facilities

Not available

Company Notes
Formerly=OXIS International, Inc. until 8-2017
Formerly=DDI Pharmaceuticals, Inc. until 9-94
Note=2-74 State of incorporation California changed to Delaware
Nasdaq
Daily Advancers
Subscribe to Our Newsletter
Stay up to date on the latest company news, industry trends and regulatory changes that affect our markets and learn about members of our community.